Cancer, Adenoid Cystic Carcinoma
DAWNDay One PharmaceuticalsCatalyst overview
Research summary
This catalyst tracks a Phase 1 data readout for Emi-Le/Emiltatug Ledadotin (Emi-Le) (B7-H4 ADC) in Cancer, Adenoid Cystic Carcinoma. The expected timing is based on the latest available company guidance and may change.
01/11/26:- Phase 1 Emi-Le ACC trial aims to deliver initial clinical data by Mid-2026. 02/24/26:- Updated Phase 1 Emi-Le ACC data expected mid-2026, confirming prior mid-2026 initial data guidance.
Verification
Confirm timing and program details against the company announcement or filing.